Researcher.Life Logo

ACS Medicinal Chemistry Letters : Impact Factor & More

eISSN: 1948-5875pISSN: 1948-5875

Aims and Scope of ACS Medicinal Chemistry Letters

ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. Founded in 2009, this online journal is published monthly by the American Chemical Society. The Editor-in-Chief is Dennis C. Liotta (Emory University, Atlanta, Georgia, USA). Less

Key Metrics

CiteScore
6.6
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
SJR
Q2Biochemistry
SNIP
0.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on ACS Medicinal Chemistry Letters

ACS Medicinal Chemistry Letters Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher AMER CHEMICAL SOC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2010
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in ACS Medicinal Chemistry Letters ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in ACS Medicinal Chemistry Letters

Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers
  • 26 Feb 2026
  • ACS Medicinal Chemistry Letters
<i>N</i> -Alkyl and <i>N</i> -Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors
  • 24 Feb 2026
  • ACS Medicinal Chemistry Letters
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
When Potency Is Not Enough: Aligning Modality, Exposure, and Biology
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
<i>Bheka Thina</i> (“Look At Us”): The Emergence of an Integrated Drug Discovery Ecosystem in South Africa
  • 22 Feb 2026
  • ACS Medicinal Chemistry Letters
Discovery of Pan-TEAD Inhibitors That Disrupt YAP-TEAD Interaction as a Potential Therapy for Gastric Cancers and Mutant KRAS and EGFR Lung Cancers
  • 26 Feb 2026
  • ACS Medicinal Chemistry Letters
<i>N</i> -Alkyl and <i>N</i> -Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors
  • 24 Feb 2026
  • ACS Medicinal Chemistry Letters
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
When Potency Is Not Enough: Aligning Modality, Exposure, and Biology
  • 23 Feb 2026
  • ACS Medicinal Chemistry Letters
<i>Bheka Thina</i> (“Look At Us”): The Emergence of an Integrated Drug Discovery Ecosystem in South Africa
  • 22 Feb 2026
  • ACS Medicinal Chemistry Letters

FAQs on ACS Medicinal Chemistry Letters